Marco HEOR is a structured platform for contrasting real-world evidence with clinical and HTA frameworks, accelerating the evidence generation process and submissions to health technology assessment bodies. Designed for HEOR teams at pharmaceutical companies.
Some answers to questions we often receive
Marco HEOR covers the leading health technology assessment bodies globally, including NICE (UK), CADTH (Canada), HAS (France), IQWiG (Germany), ICER (US), and regional bodies across Latin America.
Yes. By structuring evidence systematically and aligning it with each HTA body's framework, Marco HEOR significantly reduces the time required to prepare evidence packages.
Marco HEOR allows the explicit identification and documentation of evidence uncertainties, structuring arguments for risk-sharing agreements (MEAs) that HTA bodies may require as a condition of reimbursement.
Yes. Marco HEOR allows incorporating data from proprietary clinical studies, patient registries, and RWE in a secure and auditable environment to be contrasted with published evidence.
Yes. Marco HEOR structures and documents efficacy, safety, quality of life, and economic value evidence aligned with the requirements of the leading HTA value dossiers required by global assessment bodies.
Yes. Marco HEOR allows adapting the same body of evidence to the specific requirements of each local HTA body in parallel, maximizing HEOR team efficiency in multi-market launch strategies.
HEOR teams need to generate structured, comparable evidence for multiple HTA markets simultaneously, with limited resources and very tight timelines.
